Congenital Junctional Ectopic Tachycardia (CJET) is a rare tachyarrhythmia that remains difficult to manage with suboptimal control in most cases. Here, we report literature research on the use of Ivabradine in the treatment of pediatric Junctional Ectopic Tachycardia (JET), both congenital and postoperative, and describe the successful use of Ivabradine in combination with Flecainide for CJET therapy resistant to multiple antiarrhythmic agents. This new drug combination was effective in completely suppressing JET.Ivabradine in combination with Flecainide may be considered a new therapeutic strategy of CJET with satisfactory efficacy/tolerability ratio in patients resistant to conventional drug combinations.